162 related articles for article (PubMed ID: 20945984)
1. Biomarkers in Parkinson's disease: a funder's perspective.
Frasier M; Chowdhury S; Eberling J; Sherer T
Biomark Med; 2010 Oct; 4(5):723-9. PubMed ID: 20945984
[TBL] [Abstract][Full Text] [Related]
2. Problems associated with fluid biomarkers for Parkinson's disease.
Nyhlén J; Constantinescu R; Zetterberg H
Biomark Med; 2010 Oct; 4(5):671-81. PubMed ID: 20945980
[TBL] [Abstract][Full Text] [Related]
3. Biochemical premotor biomarkers for Parkinson's disease.
Mollenhauer B; Zhang J
Mov Disord; 2012 Apr; 27(5):644-50. PubMed ID: 22508282
[TBL] [Abstract][Full Text] [Related]
4. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease.
Hong Z; Shi M; Chung KA; Quinn JF; Peskind ER; Galasko D; Jankovic J; Zabetian CP; Leverenz JB; Baird G; Montine TJ; Hancock AM; Hwang H; Pan C; Bradner J; Kang UJ; Jensen PH; Zhang J
Brain; 2010 Mar; 133(Pt 3):713-26. PubMed ID: 20157014
[TBL] [Abstract][Full Text] [Related]
5. Parkinson disease: Progress towards a molecular biomarker for Parkinson disease.
Foulds P; Mann DM; Mitchell JD; Allsop D
Nat Rev Neurol; 2010 Jul; 6(7):359-61. PubMed ID: 20639912
[No Abstract] [Full Text] [Related]
6. α-Synuclein and DJ-1 as potential biological fluid biomarkers for Parkinson's Disease.
Waragai M; Sekiyama K; Sekigawa A; Takamatsu Y; Fujita M; Hashimoto M
Int J Mol Sci; 2010 Oct; 11(11):4257-66. PubMed ID: 21151436
[TBL] [Abstract][Full Text] [Related]
7. CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls.
Herbert MK; Eeftens JM; Aerts MB; Esselink RA; Bloem BR; Kuiperij HB; Verbeek MM
Parkinsonism Relat Disord; 2014 Jan; 20(1):112-5. PubMed ID: 24075122
[TBL] [Abstract][Full Text] [Related]
8. The role of biomarkers and imaging in Parkinson's disease.
Algarni MA; Stoessl AJ
Expert Rev Neurother; 2016; 16(2):187-203. PubMed ID: 26829357
[TBL] [Abstract][Full Text] [Related]
9. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
[TBL] [Abstract][Full Text] [Related]
10. DJ-1 and αSYN in LRRK2 CSF do not correlate with striatal dopaminergic function.
Shi M; Furay AR; Sossi V; Aasly JO; Armaly J; Wang Y; Wszolek ZK; Uitti RJ; Hasegawa K; Yokoyama T; Zabetian CP; Leverenz JB; Stoessl AJ; Zhang J
Neurobiol Aging; 2012 Apr; 33(4):836.e5-7. PubMed ID: 22019052
[TBL] [Abstract][Full Text] [Related]
11. Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease.
Shi M; Zabetian CP; Hancock AM; Ginghina C; Hong Z; Yearout D; Chung KA; Quinn JF; Peskind ER; Galasko D; Jankovic J; Leverenz JB; Zhang J
Neurosci Lett; 2010 Aug; 480(1):78-82. PubMed ID: 20540987
[TBL] [Abstract][Full Text] [Related]
12. Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease.
Waragai M; Wei J; Fujita M; Nakai M; Ho GJ; Masliah E; Akatsu H; Yamada T; Hashimoto M
Biochem Biophys Res Commun; 2006 Jul; 345(3):967-72. PubMed ID: 16707095
[TBL] [Abstract][Full Text] [Related]
13. Emerging pathways in genetic Parkinson's disease.
Lewis PA
FEBS J; 2008 Dec; 275(23):5747. PubMed ID: 19021751
[No Abstract] [Full Text] [Related]
14. Cerebrospinal fluid biomarkers in Parkinson disease.
Parnetti L; Castrioto A; Chiasserini D; Persichetti E; Tambasco N; El-Agnaf O; Calabresi P
Nat Rev Neurol; 2013 Mar; 9(3):131-40. PubMed ID: 23419373
[TBL] [Abstract][Full Text] [Related]
15. Cheek cell-derived α-synuclein and DJ-1 do not differentiate Parkinson's disease from control.
Stewart T; Sui YT; Gonzalez-Cuyar LF; Wong DT; Akin DM; Tumas V; Aasly J; Ashmore E; Aro P; Ginghina C; Korff A; Zabetian CP; Leverenz JB; Shi M; Zhang J
Neurobiol Aging; 2014 Feb; 35(2):418-20. PubMed ID: 24041968
[TBL] [Abstract][Full Text] [Related]
16. α-synuclein imaging: a critical need for Parkinson's disease research.
Eberling JL; Dave KD; Frasier MA
J Parkinsons Dis; 2013; 3(4):565-7. PubMed ID: 24192754
[TBL] [Abstract][Full Text] [Related]
17. Salivary α-synuclein and DJ-1: potential biomarkers for Parkinson's disease.
Devic I; Hwang H; Edgar JS; Izutsu K; Presland R; Pan C; Goodlett DR; Wang Y; Armaly J; Tumas V; Zabetian CP; Leverenz JB; Shi M; Zhang J
Brain; 2011 Jul; 134(Pt 7):e178. PubMed ID: 21349902
[No Abstract] [Full Text] [Related]
18. Pathological properties of the Parkinson's disease-associated protein DJ-1 in alpha-synucleinopathies and tauopathies: relevance for multiple system atrophy and Pick's disease.
Neumann M; Müller V; Görner K; Kretzschmar HA; Haass C; Kahle PJ
Acta Neuropathol; 2004 Jun; 107(6):489-96. PubMed ID: 14991385
[TBL] [Abstract][Full Text] [Related]
19. Interview with Mark Frasier: a Michael J Fox Foundation perspective on precision medicine in Parkinson's.
Frasier MA
Per Med; 2017 Jan; 14(1):13-15. PubMed ID: 29749821
[TBL] [Abstract][Full Text] [Related]
20. Value of cerebrospinal fluid α-synuclein species as biomarker in Parkinson's diagnosis and prognosis.
Parnetti L; Cicognola C; Eusebi P; Chiasserini D
Biomark Med; 2016; 10(1):35-49. PubMed ID: 26643452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
